AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Original Source: FD (FAIR DISCLOSURE) WIRE
OPERATOR: Welcome, everyone, and welcome to today's ad hoc November Conference Call. Please find the legal disclaimer on the following website. www.lionbioscience.com/investors. As a reminder, this conference is being recorded. At this time, I would like to turn the call over to your host today, Dr. Thure Etzold. Please go ahead, sir.
DR. THURE ETZOLD, COE, LION BIOSCIENCE: Thank you. Ladies and gentlemen, thank you for attending our conference call, and for your interest in LION bioscience. First I would like to highlight the structural changes and the reorganization within the Company. My colleague, Peter Willinger, who's LION's new CFO, will then present the financial details to you.
But first, I would like to comment on the perssonel changes within LION's Executive Management. LION bioscience's recently appointed Supervisory Board has reorganized the Executive Board of LION bioscience AG, effective November 17.
I was appointed Chief Executive Officer, and Peter Willinger, who has been responsible for finance department since '98, was appointed Chief Financial Officer. Joe Donahue moved from the Board and remains Head of Global Sales of LION AG, and President of LION Incorporated, LION's US subsidiary.
You may ask why there has been so many personnel changes within the Management Board in such a short timeframe. After the surprising resignation of LION's Board Members, Martin Hollenhorst and Dr. Daniel Keesman, the Supervisory Board with [Jurgen Dalemann] …